Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetic and Pharmacodynamic Studies of Efficacy, Tolerability and Safety of Higher Dosage Rifapentine for Treatment of Tuberculosis

Next Previous
Trial Profile

Pharmacokinetic and Pharmacodynamic Studies of Efficacy, Tolerability and Safety of Higher Dosage Rifapentine for Treatment of Tuberculosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rifapentine (Primary) ; Rifampicin
  • Indications Pulmonary tuberculosis; Tuberculosis
  • Focus Biomarker; Pharmacogenomic; Pharmacokinetics

Most Recent Events

  • 12 Jul 2021 Results of a longitudinal model-based biomarker analysis of exposure response of data pooled from 2 clinical trials (Study 29 and study 29X) published in the Antimicrobial Agents and Chemotherapy
  • 16 Jul 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 16 Jul 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top